Back to Search
Start Over
Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
- Source :
- Clinical Sarcoma Research, 9, Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-11 (2019), Clinical Sarcoma Research
- Publication Year :
- 2019
-
Abstract
- Background Conventional chondrosarcomas are malignant cartilage tumors considered radioresistant. Nevertheless, retrospective series show a small but significant survival benefit for patients with locally advanced disease treated with radiotherapy. And, in daily practice when considered inoperable their irradiation is an accepted indication for proton beam radiotherapy. Therefore, we investigated the sensitivity of chondrosarcoma cell lines and -tissue samples towards radiotherapy and screened for biomarkers to identify predictors of radiosensitivity. Methods Proliferation and clonogenic assays were performed in chondrosarcoma cell lines after γ-radiation in combination with mutant IDH1 inhibitor AGI-5198. In addition, glutathione levels were measured using mass spectrometry. Chondrosarcoma tumor explants were irradiated after which γ-H2AX foci were counted. Mutation analysis was performed using the Ion AmpliSeq™ Cancer Hotspot Panel and immunohistochemical staining’s were performed for P-S6, LC-3B, P53, Bcl-2, Bcl-xl and Survivin. Results were correlated with the number of γ-H2AX foci. Results Chondrosarcoma cell lines were variably γ-radiation resistant. No difference in radiosensitivity, nor glutathione levels was observed after treatment with AGI-5198. Irradiated chondrosarcoma patient tissue presented a variable increase in γ-H2AX foci compared to non-radiated tissue. Samples were divided into two groups, high and low radioresistant, based on the amount of γ-H2AX foci. All four highly resistant tumors exhibited mutations in the pRb pathway, while none of the less radioresistant tumors showed mutations in these genes. Conclusions Chondrosarcoma cell lines as well as primary tumors are variably radioresistant, particularly in case of a defective Rb pathway. Whether selection for radiotherapy can be based upon an intact Rb pathway should be further investigated. Electronic supplementary material The online version of this article (10.1186/s13569-019-0119-0) contains supplementary material, which is available to authorized users.
- Subjects :
- 0301 basic medicine
medicine.medical_treatment
Cell cycle alterations
Chondrosarcoma
lcsh:RC254-282
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Radioresistance
Survivin
Radiotherapy resistance
medicine
Radiosensitivity
Clonogenic assay
business.industry
Research
Cancer
medicine.disease
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
3. Good health
Radiation therapy
030104 developmental biology
Oncology
030220 oncology & carcinogenesis
Cancer research
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Clinical Sarcoma Research, 9, Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-11 (2019), Clinical Sarcoma Research
- Accession number :
- edsair.doi.dedup.....00feaa397f954a3a5bad4a53721432d4